Intranasal delivery of cannabinoids
AssigneeNanomerics LTD
InventorsIjeoma UCHEGBU, Ilona KUBAJEWSKA, Andreas SCHATZLEIN
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.
Claims49
A method of treatment comprising administering to a human or animal a composition comprising a cannabinoid and an amphiphilic carbohydrate compound, wherein the composition is intranasally administered to the human or animal body.
A composition comprising a cannabinoid and an amphiphilic carbohydrate compound for use in a method of treating a human or animal by intranasal administration.
A method or composition for use according to any preceding claim wherein the composition is in the form of nanoparticles.
A method or composition for use according to any preceding claim wherein the ratio of cannabinoid to amphiphilic carbohydrate compound is between 0.5:10 to 5:10 g g−1.
A method or composition for use according to any preceding claim wherein the cannabinoid is delivered to the brain of the human or animal body.
A method or composition for use according to any preceding claim wherein the cannabinoid is a non-psychoactive cannabinoid and is preferably cannabidiol.
A method or composition for use according to any preceding claim wherein the amphiphilic carbohydrate compound is a chitosan derivative.
A method or composition for use according to any preceding claim wherein the amphiphilic carbohydrate compound comprises the general formula:
- wherein a+b+c+d=1.000 and
- a is between 0.01 and 0.970
- b is between 0.01 and 0.990,
- c is between 0.0001 and 0.970, and
- d is between 0.01 and 0.990;
- and wherein:
- X is a hydrophobic group;
- R1, R2 and R3 are independently selected from a substituted or unsubstituted alkyl group;
- R4, R5, R6 and R10 are independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;
- R7 may be present or absent and, when present, is an unsubstituted or substituted alkyl group, an unsubstituted or substituted amine group or a substituted or unsubstituted amide group;
- R3 and R9 are independently selected from hydrogen and either a substituted or unsubstituted alkyl group, a substituted or unsubstituted ether group, or a substituted or unsubstituted alkene group;
- or a salt thereof.
A pharmaceutical composition suitable for intranasal administration comprising an amphiphilic carbohydrate compound and a non-psychoactive cannabinoid and one or more pharmaceutically acceptable excipients.
A pharmaceutical composition comprising GCPQ and a cannabinoid and one or more pharmaceutically acceptable excipients.
A composition comprising GCPQ and a cannabinoid wherein the GCPQ has a palmitoylation level in the range 11-31 mole % and a quaternisation level in the range 8-17 mole %, and the ratio of GCPQ:cannabinoid is between 1:1 and 1:10.
Dependencies are inferred from the claim text.